Prelude Therapeutics goes public with $158M IPO; stock up nearly 50% in early trading

The company is the fifth Philadelphia-area life sciences companies to go public this year through an IPO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.